DekaBank Deutsche Girozentrale
SMMT icon

DekaBank Deutsche Girozentrale’s Summit Therapeutics SMMT Stock Holding History

DekaBank Deutsche Girozentrale’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-100,000
Closed -$531K – 1365
2022
Q4 		$531K Buy
+100,000
New +$182K ﹤0.01% 1020

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return

DekaBank Deutsche Girozentrale's SMMT Position: Q1 2023 in Review

DekaBank Deutsche Girozentrale sold out of Summit Therapeutics (SMMT) in Q1 2023, closing a stake of 100,000 shares — an estimated $531K sold.

DekaBank Deutsche Girozentrale first reported a position in SMMT in Q4 2022 and held it in 1 quarter. The position peaked at $531K in Q4 2022. 91 funds tracked by Wall St. Rank hold SMMT as of Q1 2023.

  • DekaBank Deutsche Girozentrale reported no remaining Summit Therapeutics position as of Q1 2023 after selling out during the quarter.
  • DekaBank Deutsche Girozentrale sold 100,000 Summit Therapeutics shares in Q1 2023, an estimated $531K.
  • DekaBank Deutsche Girozentrale first reported a position in Summit Therapeutics in Q4 2022 and held it in 1 quarter.
  • DekaBank Deutsche Girozentrale's Summit Therapeutics position peaked at $531K in Q4 2022.
  • 91 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2023.

Based on DekaBank Deutsche Girozentrale's 13F filing for Q1 2023, filed 24 Apr 2023.